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POST-AMI DRUGTHERAPY PERSISTENCE AND RISK OF
REINFARCTION IN A MEDICAID POPULATION
Shaya FT, Gu A
University of Maryland School of Pharmacy, Baltimore, MD, USA
OBJECTIVES: To assess the effect of persistence on statin,
a-blocker, or Calcium Channel Blocker (CCB) therapy, on the
risk of reinfarction in a Medicaid high-risk, largely female,
predominantly minority population. METHODS: Prospective
nonconcurrent cohort, longitudinal data analysis of medical
and pharmacy claims of Acute Myocardial Infarction (AMI)
Medicaid MCO patients, observed between January 1, 2002 and
December 31, 2004. Cox proportional hazards models were used
to predict the likelihood of a reinfarction as a function of persis-
tence on the ﬁrst medication post-AMI, adjusting for age, race,
sex, heart disease and other comorbidities, and other medica-
tions. RESULTS: Among 515 AMI patients (58% female and
54% African American), hypertension (91%) and heart disease
(81%) were the most prevalent comorbidities; most initial AMIs
were non-transmural. Discontinuation of statin, a-blocker,
or CCB post-AMI increased the likelihood of a reinfarction
(HR = 1.66; 95% CI 1.03–2.69). Concurrent heart disease,
hyperlipidemia, or renal disease signiﬁcantly increased the like-
lihood of a reinfarction. Age, race and sex did not signiﬁcantly
predict the likelihood of reinfarction. CONCLUSION: Persis-
tence on the ﬁrst post-AMI preventive medication is effective at
avoiding a reinfarction. Concomitant heart disease, renal disease
and hyperlipidemia increases the likelihood of a reinfarction.
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COST-EFFECTIVENESS OF ROSUVASTATINVERSUS
ATORVASTATIN, SIMVASTATIN,AND PRAVASTATIN FROM A
CANADIAN HEALTH CARE PERSPECTIVE
Costa-Scharplatz M1, Beamer B2, Frial T2, Gandhi SK3
1AstraZeneca, Södertälje, Sweden, 2AstraZeneca, Mississauga, ON,
Canada, 3AstraZeneca, LP,Wilmington, DE, USA
OBJECTIVES: To estimate cost-effectiveness of rosuvasta-
tin (RSV) versus atorvastatin (ATV); simvastatin (SMV), and
pravastatin (PRV) in managing lipid proﬁle parameters from
a Canadian system perspective. METHODS: Annual cost-
effectiveness ratios of RSV, ATV, SMV, and PRV were estimated
in patients with hypercholesterolemia in terms of cost per percent
LDL-C and TC/HDL-C and ApoB/ApoA-I reductions and
Canadian guideline LDL-C goal attainment. Efﬁcacy data were
from a randomized, open-label trial including 2,268 adults
(Jones et al, 2004). Drug costs [Can$, branded ATV and RSV;
generic (g) SMV and gPRV] and dose utilization pattern within
each statin from the Canadian province of British Columbia
(March 2007) were used. Probabilistic sensitivity analysis was
performed. RESULTS: RSV10 had lowest annual cost per
percent reduction in LDL-C ($10.79), TC/HDL ($13.29) and
ApoB/ApoA-I ($12.11), followed by gSMV80 ($11.19, $14.00,
$13.20). After aggregating statin doses based on utilization
pattern, RSV provided lowest mean annual cost per percent
reduction in LDL-C ($11.03), TC/HDL ($13.55) and ApoB/
ApoA-I ($12.39), followed by gSMV ($14.04, $16.96, $15.90),
ATV ($16.93, $20.81, $19.48) and gPRV ($16.98, $20.01,
$17.84), respectively. Cost per patient at goal was lowest for RSV
($603.46) followed by gPRV ($687.23), gSMV ($719.67) and
ATV ($934.12). RSV was more effective and less costly than ATV
on all assessed effectiveness measures. Comparing rosuvastatin to
gSMV and gPRV, the value of an additional one percent reduc-
tion in LDL-C was $2.11 and $3.99, TC/HDL was $2.72 and
$5.17, ApoB/ApoA-I was $2.30 and $4.88, and per one addi-
tional patient to goal was $143.64 and $373.91, respectively.
Cost-effectiveness acceptability curve showed that RSV was the
most cost-effective statin over a broad range of “willingness-to-
pay” values per unit of clinical effect. CONCLUSION: Irrespec-
tive of effectiveness measure chosen, rosuvastatin can be
considered as most cost-effective statin compared with ator-
vastatin, generic simvastatin and generic pravastatin in the
Canadian province of British Columbia.
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DO DIFFERENCES IN DOSE IMPACT ADHERENCETO
SINGLE-PILL AMLODIPINE/ATORVASTATINVERSUS 2-PILL
AMLODIPINE AND ATORVASTATIN?
Tang SSK1, Patel BV2, Leslie RS2,Thiebaud P2, Nichol MB3,
Solomon HA1,Trainer JB1, Foody JM4
1Pﬁzer Inc, New York, NY, USA, 2MedImpact Healthcare Systems, Inc,
San Diego, CA, USA, 3University of Southern California, Los Angeles,
CA, USA, 4Yale University, New Haven, CT, USA
OBJECTIVES: To determine whether single-pill amlodipine
besylate/atorvastatin calcium (SPAA) use achieved greater adher-
ence vs. 2-pill amlodipine besylate and atorvastatin calcium
(2PAA), at low, high, and European doses. METHODS: This
study assessed drug beneﬁts managed by a large U.S. Pharmacy
Beneﬁt Management company. Patients newly initiated on either
a CCB or a statin within 30 days of each other were followed-up
for 6 months. Sub-analyses were conducted with patients on
SPAA (N = 795) and 2PAA (N = 735), and both groups were
stratiﬁed based on dose; SPAA vs 2PAA comparisons were made
for low-dose (2.5, 5 mg) and high-dose (10 mg) amlodipine,
low-dose (10 mg) and high-dose (20, 40, 80 mg) atorvastatin,
and the European doses of SPAA (5/10 mg, 10/10 mg). Adher-
ence was measured as proportion of days covered (PDC) based
on the days that both amlodipine and atorvastatin were supplied
over 6 months. Adherence was considered achieved if PDC was
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